特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

カテーテル関連血流感染症(CRBSI)- 市場洞察、疫学、市場予測

Catheter-related bloodstream infection (CRBSI) Market Insight, Epidemiology and Market Forecast - 2030

発行 DelveInsight Business Research LLP 商品コード 909903
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.61円で換算しております。
カテーテル関連血流感染症(CRBSI)- 市場洞察、疫学、市場予測 Catheter-related bloodstream infection (CRBSI) Market Insight, Epidemiology and Market Forecast - 2030
出版日: 2020年01月01日 ページ情報: 英文 150 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、スペイン、イタリア、日本)のカテーテル関連血流感染症(CRBSI)の罹患数は、2017年に66万7,753人と推計され、2028年にかけてその数は増加すると予測されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、スペイン、イタリア、日本)のカテーテル関連血流感染症(CRBSI)市場について調査し、疾患の概要、各国の疫学的予測(罹患数・診断数)、治療アルゴリズム、現行治療、アンメットニーズ、上市済み治療薬、適応外薬、新薬の概要、各国の市場規模の推移と予測などについてまとめています。

目次

第1章 重要洞察

第2章 カテーテル関連血流感染症(CRBSI)市場の概要

  • 分布状況(実績値)
  • 分布状況(予測値)

第3章 カテーテル関連血流感染症(CRBSI):疾患背景と概要

  • イントロダクション
  • 中心ライン関連血流感染症(CLABSI)とカテーテル関連血流感染症(CRBSI)の違い
  • カテーテル関連血流感染症(CRBSI)の原因
    • 微生物
    • 血管内デバイス
  • カテーテル関連血流感染症(CRBSI)の危険因子
  • カテーテル関連血流感染症(CRBSI)の病因
  • カテーテル関連血流感染症(CRBSI)の診断
  • カテーテル関連血流感染症(CRBSI)の診断ガイドライン

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国のカテーテル関連血流感染症(CRBSI)の総罹患数
  • 主要7カ国のカテーテル関連血流感染症(CRBSI)の診断数
  • 主要7カ国のカテーテル関連血流感染症(CRBSI)の診断数:起炎菌別
  • キーオピニオンリーダーの意見

第5章 米国の疫学

  • 仮定と根拠
  • カテーテル関連血流感染症(CRBSI)の総罹患数
  • カテーテル関連血流感染症(CRBSI)の総診断数
  • カテーテル関連血流感染症(CRBSI)の診断数:起炎菌別

第6章 欧州5カ国の疫学

  • ドイツの疫学
    • 仮定と根拠
    • カテーテル関連血流感染症(CRBSI)の総罹患数
    • カテーテル関連血流感染症(CRBSI)の総診断数
    • カテーテル関連血流感染症(CRBSI)の診断数:起炎菌別
  • フランスの疫学
  • イタリアの疫学
  • スペインの疫学
  • 英国の疫学

第7章 日本疫学

  • 仮定と根拠
  • カテーテル関連血流感染症(CRBSI)の総罹患数
  • カテーテル関連血流感染症(CRBSI)の総診断数
  • カテーテル関連血流感染症(CRBSI)の診断数:起炎菌別

第8章 治療アルゴリズム・現行治療

  • カテーテル関連血流感染症(CRBSI)の治療
    • 全般
    • 短期中心静脈/動脈CRBSI
    • 長期中心静脈CRBSI
  • 治療ガイドライン
  • 予防ガイドライン(CRBSI)

第9章 アンメットニーズ

第10章 上市済み医薬品

  • Neutrolin: CorMedix
    • 製品説明
    • 作用機序
    • 規制マイルストーン
    • 臨床開発
    • 臨床試験情報
    • 安全性と有効性
    • 製品プロファイル
  • Taurosept:Geistlich Pharma
  • Taurolock:TauroPharm GmbH
  • IntraLock:Fresenius Medical Care

第11章 適応外薬

  • 抗菌剤
    • ダプトマイシン
    • バンコマイシン
    • セファゾリン
    • アンピシリン
    • シプロフロキサシン
    • アミカシン
    • テイコプラニン
  • 抗真菌剤
    • フルコナゾール
    • アムホテリシンB

第12章 新薬

  • Mino-Lok:Citius Pharmaceuticals
    • 製品説明
    • その他の発達活動
    • 臨床開発
    • 製品プロファイル

第13章 主要7カ国市場の分析

  • 主な調査結果
  • 総市場規模
  • 市場規模:治療薬別

第14章 米国:市場の見通し

  • 米国の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第15章 欧州5カ国:市場の見通し

  • ドイツの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • フランスの市場規模
  • イタリアの市場規模
  • スペインの市場規模
  • 英国の市場規模

第16章 日本市場の見通し

  • 日本の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第17章 市場の成長要因

第18章 市場の障壁

第19章 付録

  • 調査方法

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

図表

List of Tables

  • Table 1 : 7MM Catheter-related bloodstream infection (CRBSI) Epidemiology (2017-2030)
  • Table 2 : 7MM Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Catheter-related bloodstream infection (CRBSI) Epidemiology in Germany (2017-2030)
  • Table 6 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Catheter-related bloodstream infection (CRBSI) Epidemiology in France (2017-2030)
  • Table 8 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Catheter-related bloodstream infection (CRBSI) Epidemiology in Italy (2017-2030)
  • Table 10 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Catheter-related bloodstream infection (CRBSI) Epidemiology in Spain (2017-2030)
  • Table 12 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Catheter-related bloodstream infection (CRBSI) Epidemiology in the UK (2017-2030)
  • Table 14 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Catheter-related bloodstream infection (CRBSI) Epidemiology in Japan (2017-2030)
  • Table 16 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Catheter-related bloodstream infection (CRBSI) Epidemiology (2017-2030)
  • Figure 2 : 7MM Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Catheter-related bloodstream infection (CRBSI) Epidemiology in the United States (2017-2030)
  • Figure 4 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Catheter-related bloodstream infection (CRBSI) Epidemiology in Germany (2017-2030)
  • Figure 6 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Catheter-related bloodstream infection (CRBSI) Epidemiology in France (2017-2030)
  • Figure 8 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Catheter-related bloodstream infection (CRBSI) Epidemiology in Italy (2017-2030)
  • Figure 10 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Catheter-related bloodstream infection (CRBSI) Epidemiology in Spain (2017-2030)
  • Figure 12 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Catheter-related bloodstream infection (CRBSI) Epidemiology in the UK (2017-2030)
  • Figure 14 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Catheter-related bloodstream infection (CRBSI) Epidemiology in Japan (2017-2030)
  • Figure 16 : Catheter-related bloodstream infection (CRBSI) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)
目次
Product Code: DIMI0654

DelveInsight's "Catheter-related bloodstream infection (CRBSI) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Catheter-related bloodstream infection (CRBSI), historical and forecasted epidemiology as well as the Catheter-related bloodstream infection (CRBSI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Catheter-related bloodstream infection (CRBSI) market report provides current treatment practices, emerging drugs, Catheter-related bloodstream infection (CRBSI) market share of the individual therapies, current and forecasted Catheter-related bloodstream infection (CRBSI) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Catheter-related bloodstream infection (CRBSI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Catheter-related bloodstream infection (CRBSI) Disease Understanding and Treatment Algorithm

The DelveInsight Catheter-related bloodstream infection (CRBSI) market report gives a thorough understanding of the Catheter-related bloodstream infection (CRBSI) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Catheter-related bloodstream infection (CRBSI).

Treatment

It covers the details of conventional and current medical therapies available in the Catheter-related bloodstream infection (CRBSI) market for the treatment of the condition. It also provides Catheter-related bloodstream infection (CRBSI) treatment algorithms and guidelines in the United States, Europe, and Japan.

Catheter-related bloodstream infection (CRBSI) Epidemiology

The Catheter-related bloodstream infection (CRBSI) epidemiology division provide insights about historical and current Catheter-related bloodstream infection (CRBSI) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Catheter-related bloodstream infection (CRBSI) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Catheter-related bloodstream infection (CRBSI) Epidemiology

The epidemiology segment also provides the Catheter-related bloodstream infection (CRBSI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Catheter-related bloodstream infection (CRBSI) Drug Chapters

Drug chapter segment of the Catheter-related bloodstream infection (CRBSI) report encloses the detailed analysis of Catheter-related bloodstream infection (CRBSI) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Catheter-related bloodstream infection (CRBSI) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Catheter-related bloodstream infection (CRBSI) treatment.

Catheter-related bloodstream infection (CRBSI) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Catheter-related bloodstream infection (CRBSI) treatment.

Catheter-related bloodstream infection (CRBSI) Market Outlook

The Catheter-related bloodstream infection (CRBSI) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Catheter-related bloodstream infection (CRBSI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Catheter-related bloodstream infection (CRBSI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Catheter-related bloodstream infection (CRBSI) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Catheter-related bloodstream infection (CRBSI) market in 7MM.

The United States Market Outlook

This section provides the total Catheter-related bloodstream infection (CRBSI) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Catheter-related bloodstream infection (CRBSI) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Catheter-related bloodstream infection (CRBSI) market size and market size by therapies in Japan is also mentioned.

Catheter-related bloodstream infection (CRBSI) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Catheter-related bloodstream infection (CRBSI) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Catheter-related bloodstream infection (CRBSI) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Catheter-related bloodstream infection (CRBSI) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Catheter-related bloodstream infection (CRBSI) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Catheter-related bloodstream infection (CRBSI) emerging therapies.

Reimbursement Scenario in Catheter-related bloodstream infection (CRBSI)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Catheter-related bloodstream infection (CRBSI) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Catheter-related bloodstream infection (CRBSI) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Catheter-related bloodstream infection (CRBSI) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Catheter-related bloodstream infection (CRBSI), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Catheter-related bloodstream infection (CRBSI) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Catheter-related bloodstream infection (CRBSI) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Catheter-related bloodstream infection (CRBSI) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Catheter-related bloodstream infection (CRBSI) market

Report Highlights

  • In the coming years, Catheter-related bloodstream infection (CRBSI) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Catheter-related bloodstream infection (CRBSI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Catheter-related bloodstream infection (CRBSI). Launch of emerging therapies will significantly impact the Catheter-related bloodstream infection (CRBSI) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Catheter-related bloodstream infection (CRBSI)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Catheter-related bloodstream infection (CRBSI) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Catheter-related bloodstream infection (CRBSI) Pipeline Analysis
  • Catheter-related bloodstream infection (CRBSI) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Catheter-related bloodstream infection (CRBSI) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Catheter-related bloodstream infection (CRBSI) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Catheter-related bloodstream infection (CRBSI) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Catheter-related bloodstream infection (CRBSI) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Catheter-related bloodstream infection (CRBSI) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Catheter-related bloodstream infection (CRBSI) market size during the forecast period (2017-2030)?
  • At what CAGR, the Catheter-related bloodstream infection (CRBSI) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Catheter-related bloodstream infection (CRBSI) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Catheter-related bloodstream infection (CRBSI) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Catheter-related bloodstream infection (CRBSI)?
  • What is the historical Catheter-related bloodstream infection (CRBSI) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Catheter-related bloodstream infection (CRBSI) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Catheter-related bloodstream infection (CRBSI)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Catheter-related bloodstream infection (CRBSI) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Catheter-related bloodstream infection (CRBSI) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Catheter-related bloodstream infection (CRBSI) in the USA, Europe, and Japan?
  • What are the Catheter-related bloodstream infection (CRBSI) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Catheter-related bloodstream infection (CRBSI)?
  • How many therapies are developed by each company for Catheter-related bloodstream infection (CRBSI) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Catheter-related bloodstream infection (CRBSI) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Catheter-related bloodstream infection (CRBSI) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Catheter-related bloodstream infection (CRBSI) and their status?
  • What are the key designations that have been granted for the emerging therapies for Catheter-related bloodstream infection (CRBSI)?
  • What are the global historical and forecasted market of Catheter-related bloodstream infection (CRBSI)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Catheter-related bloodstream infection (CRBSI) market
  • To understand the future market competition in the Catheter-related bloodstream infection (CRBSI) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Catheter-related bloodstream infection (CRBSI) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Catheter-related bloodstream infection (CRBSI) market
  • To understand the future market competition in the Catheter-related bloodstream infection (CRBSI) market

Table of Contents

1. Key Insights

2. Executive Summary of Catheter-related bloodstream infection (CRBSI)

3. Competitive Intelligence Analysis for Catheter-related bloodstream infection (CRBSI)

4. Catheter-related bloodstream infection (CRBSI): Market Overview at a Glance

  • 4.1. Catheter-related bloodstream infection (CRBSI) Total Market Share (%) Distribution in 2017
  • 4.2. Catheter-related bloodstream infection (CRBSI) Total Market Share (%) Distribution in 2030

5. Catheter-related bloodstream infection (CRBSI): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Catheter-related bloodstream infection (CRBSI) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Catheter-related bloodstream infection (CRBSI) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Catheter-related bloodstream infection (CRBSI) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Catheter-related bloodstream infection (CRBSI) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Catheter-related bloodstream infection (CRBSI) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Catheter-related bloodstream infection (CRBSI) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Catheter-related bloodstream infection (CRBSI) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Catheter-related bloodstream infection (CRBSI) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Catheter-related bloodstream infection (CRBSI) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Catheter-related bloodstream infection (CRBSI) Treatment and Management
  • 8.2. Catheter-related bloodstream infection (CRBSI) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Catheter-related bloodstream infection (CRBSI) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Catheter-related bloodstream infection (CRBSI): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Catheter-related bloodstream infection (CRBSI) Market Size in 7MM
  • 13.3. Catheter-related bloodstream infection (CRBSI) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Catheter-related bloodstream infection (CRBSI) Total Market Size in the United States
    • 15.1.2. Catheter-related bloodstream infection (CRBSI) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Catheter-related bloodstream infection (CRBSI) Total Market Size in Germany
    • 15.3.2. Catheter-related bloodstream infection (CRBSI) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Catheter-related bloodstream infection (CRBSI) Total Market Size in France
    • 15.4.2. Catheter-related bloodstream infection (CRBSI) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Catheter-related bloodstream infection (CRBSI) Total Market Size in Italy
    • 15.5.2. Catheter-related bloodstream infection (CRBSI) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Catheter-related bloodstream infection (CRBSI) Total Market Size in Spain
    • 15.6.2. Catheter-related bloodstream infection (CRBSI) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Catheter-related bloodstream infection (CRBSI) Total Market Size in the United Kingdom
    • 15.7.2. Catheter-related bloodstream infection (CRBSI) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Catheter-related bloodstream infection (CRBSI) Total Market Size in Japan
    • 15.8.3. Catheter-related bloodstream infection (CRBSI) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Catheter-related bloodstream infection (CRBSI)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight